Bulk panels average signals across billions of cells and call it ‘normal.’ CellWise reads 400+ biomarker genes across immune cell populations, shows you which cells are dysregulated and why, and names the exact follow-up labs to order next.
The gaps between a symptomatic patient and an actionable answer.
Bulk panels average signals across billions of cells and call it normal. CellWise reads gene expression across 400+ biomarker genes across immune cell populations to show which cells are dysregulated, and why.
Without objective molecular data, treatment becomes iteration. The immuno-metabolic phenotype and missing-biomarker interrogation name the exact workup the pattern warrants before you order a conventional test.
Complex autoimmune and inflammatory cases wander between referrals. CellWise converges scattered signals into a single narrative that points straight at the right panel.
The clinical home base. Use-case assessments, immuno-metabolic phenotyping, the therapeutic target map, stress profiling, and more, all in one report.
The quantitative, visual view of the patient's raw biomarker data, shown as a population-vs-patient overview.
A filterable, gene-level interface over the patient's complete dataset, exposing the top cell populations carrying each signal.
Test a clinical hypothesis against the patient's own molecular data and re-run it in seconds.
Assay-independent surveillance across dosing phases, peptide-specific labs, and wearable trends, with no repeat sequence required.
Immune age, senescence, and the 12 hallmarks from one PBMC sample, for cell-resolved biological aging.
Re-assay a patient and see the gene-expression deltas across key biomarkers, so you see what has shifted since the last screen.
Three reviewers read the same donor in isolation, and each surfaced the same contraindication and the same targeted labs a standard panel would never generate.
The 'Very High' autoimmune risk with the CXCL10/BAFF/IFN signature is clinically coherent and would prompt me to order an ANA panel, dsDNA, and complement levels before proceeding with any immunostimulatory peptides. The report even lists the specific missing biomarkers (Anti-SSA/Ro, Anti-SSB/La, C3/C4), which is genuinely useful chart prep.
This is the resolution root-cause medicine has always needed. It tells me which cells are inflamed, not just that inflammation exists.
It named three follow-up labs I’d have reached only after two more visits of trial and error.
Join the founding pilot: up to five of your own patients at $1,485 each, 29% below the standard rate, invoiced only for the ones you send. Founding rates lock for twelve months if you go forward, and every pilot practice is a design partner with a say on what gets built. Open to a limited cohort of functional and integrative practices.